相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice
Adeline YL Lim et al.
BMC Pharmacology & Toxicology (2010)
Differential Effect of Imatinib and Synergism of Combination Treatment with Chemotherapeutic Agents in Malignant Glioma Cells
Huan Ren et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2009)
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours
Sylvain Baruchel et al.
EUROPEAN JOURNAL OF CANCER (2009)
Reduced exposure of imatinib after coadministration with acetaminophen in mice
Inthisham Nassar et al.
INDIAN JOURNAL OF PHARMACOLOGY (2009)
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2009)
In situ mouse carotid perfusion model:: glucose and cholesterol transport in the eye and brain
Julie Cattelotte et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2008)
Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood-brain barrier
Sebastien Bihorel et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report
Abdullah Altintas et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
Annick Desjardins et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?
Rhonda Roedler et al.
ANNALS OF PHARMACOTHERAPY (2007)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Drug interactions in cancer therapy
Charity D. Scripture et al.
NATURE REVIEWS CANCER (2006)
Metabolism and disposition of imatinib mesylate in healthy volunteers
HP Gschwind et al.
DRUG METABOLISM AND DISPOSITION (2005)
Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy
RL Page et al.
ANNALS OF PHARMACOTHERAPY (2005)
The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil
OJ Naderer et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Clinical pharmacokinetics of imatinib
B Peng et al.
CLINICAL PHARMACOKINETICS (2005)
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates
K Neville et al.
CLINICAL CANCER RESEARCH (2004)
C-kit expression in sarcomatoid renal cell carcinoma:: Potential therapy with imatinib
M Castillo et al.
JOURNAL OF UROLOGY (2004)
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia
NC Wolff et al.
BLOOD (2003)
Pharmacokinetics of metronidazole in rat blood, brain and bile studied by microdialysis coupled to microbore liquid chromatography
TH Tsai et al.
JOURNAL OF CHROMATOGRAPHY A (2003)
Pharmacology of imatinib (STI571)
E Buchdunger et al.
EUROPEAN JOURNAL OF CANCER (2002)
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation
CJ Matheny et al.
PHARMACOTHERAPY (2001)
分享论文
